灵康药业:2024年报净利润-1.31亿 同比增长13.25%

Financial Performance - The company reported a basic earnings per share of -0.1800 yuan for 2024, an improvement of 14.29% compared to -0.2100 yuan in 2023 [1] - The net profit for 2024 was -1.31 billion yuan, showing a 13.25% improvement from -1.51 billion yuan in 2023 [1] - Operating revenue increased significantly to 3.8 billion yuan, a 92.89% increase from 1.97 billion yuan in 2023 [1] - The return on equity was -15.32% for 2024, slightly worse than -14.42% in 2023 [1] - The net asset per share decreased to 0.98 yuan, down 15.52% from 1.16 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 45,179.74 million shares, accounting for 62.65% of the circulating shares, a decrease of 2,995.86 million shares from the previous period [2] - Lingkang Holdings Group Limited remains the largest shareholder with 33,965.28 million shares, unchanged from the previous report [3] - Wang Wenan reduced his holdings by 85.00 million shares, while several new shareholders entered the top ten list [3] Dividend Policy - The company has announced no distribution or capital increase for the current period [5]